Pola-ZR-Glo for older patients with large B‑cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-center, open-label, single-arm Phase 2 study testing the Pola‑ZR‑Glo combination (polatuzumab vedotin, zanubrutinib, lenalidomide, and glofitamab) in older, treatment‑naive patients with large B‑cell lymphoma. Eligible patients are aged 70 or older, classified as unfit or frail by comprehensive geriatric assessment or who decline standard immunochemotherapy, have ECOG 0–2, and measurable disease. Participants receive the combination regimen and are followed for tumor response and safety outcomes, including monitoring for treatment-related adverse events. All treatment and follow-up are conducted at Ruijin Hospital in Shanghai.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients must satisfy all of the following criteria to be enrolled in the study:

* Histologically-confirmed large B-cell lymphoma (without central nervous system involvement)
* Aged ≥ 70 years old with comprehensive geriatric assessment stratified as unfit or frail, or those who decline immunochemotherapy.
* Eastern Cooperative Oncology Group Performance Status 0-2
* At least 1 measurable site of disease (defined as lymph nodes with the long diameters longer than 1.5cm, or extra-nodal sites with the long diameters longer than 1.0cm; meanwhile, any lesion site with at least 2 measurable vertical diameters)
* Life expectancy of at least 3 months determined by researchers
* The patient or his or her legal representative must provide written informed consent prior to any special examination or procedure for the research.
* Anti-lymphoma drugs have not been used before (except glucocorticoids)

Exclusion Criteria:

Presence of any of the following criteria will exclude a patient from enrollment:

* Uncontrolled blood clotting disorders, connective tissue diseases, serious infectious diseases and other diseases
* Laboratory measures meet the following criteria at screening (unless caused by lymphoma):

Neutrophils\<1.0×10\^9/L Platelets\<75×10\^9/L ALT or AST is 2.5 times higher than the upper limits of normal (ULN), serum bilirubin are 1.5 times higher than the ULN.

eGFR is lower than 30ml/min/1.73m\^2 (according to Cockcroft-Gault Equation or MDRD Equation).

* uncontrollable or significant cardiovascular diseases, including but not limited to: Left ventricular ejection fraction\<50% Cardiomyopathy, such as dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy QTc prolongation with clinical significance, QTc interval\>470ms (females) or 480ms (males), type 2 second-degree atrioventricular block or third-degree atrioventricular block
* Patients with HbsAg positive are required to have HBV DNA\<1.0×10\^3 IU/ml before entering the group. In addition, if the patient is HBsAg negative but HBcAb positive (regardless of HBsAb status), HBV DNA test is also required, and HBV DNA\<1.0×10\^3 IU/ml is required before entering the group
* Patients with psychiatric disorders or patients who are known or suspected to be unable to fully comply with the study protocol
* HIV-infected patients
* History of stroke or intracranial hemorrhage within 6 months prior to start of therapy
* Other medical conditions determined by the researchers that may affect the study

Where it's running

• Ruijin Hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Weili Zhao
• Email: zwl_trial@163.com
• Phone: +862164370045 Ext. 610707

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

  A group of elderly patients with newly diagnosed diffuse large B-cell lymphoma will try a lighter chemotherapy approach using three targeted drugs to see if it works and is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07012980

• Polatuzumab vedotin with Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in untreated DLBCL (MCD/BN2/N1)

  This study tests a targeted combination therapy to see if it can treat previously untreated DLBCL with specific molecular subtypes.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07608978

• Evaluating Glofitamab with Venetoclax and Zanubrutinib for high-risk Mantle-cell Lymphoma

  This study is testing a new combination of treatments for people with high-risk Mantle-cell Lymphoma to see if it helps them better than current options.

  Recruiting at 16 sites Phase 2 The Lymphoma Academic Research Organisation · Bruges and 15 other locations · NCT06558604

• Treatment for relapsed or refractory diffuse large B-cell lymphoma using a combination of drugs

  This study is testing a new combination of drugs to see if it can help people aged 18 to 75 with relapsed or refractory diffuse large B-cell lymphoma feel better and improve their chances of recovery.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hanzhou, Zhejiang · NCT06554600

• Comparing Pola-ZR2 and ZR2 for treating elderly patients with diffuse large B-cell lymphoma

  This study is testing if adding a new drug called polatuzumab vedotin to a standard treatment helps older patients with diffuse large B-cell lymphoma feel better and improve their outcomes.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT06522555

• Combination of drugs for treating relapsed large B-cell lymphoma before and after CAR-T therapy

  This study is testing a combination of three drugs to see if they can help people with relapsed large B-cell lymphoma feel better before and after CAR-T therapy.

  Recruiting at 5 sites Phase 2 University College, London · London and 4 other locations · NCT06071871

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.